Biotech hot picks spotlight Xenon, United Therapeutics and Axsome as Phase III data and FDA decisions approach.

As global markets grapple with volatility and shifts in investor sentiment, the Asian market continues to present unique ...

Biotech stocks continue to outperform in the current stock market rally, as Dow Jones index component and industry giant AmgenAMGN, along with Gilead SciencesGILD, Vertex PharmaceuticalsVRTX, ...

Among the 22 companies under coverage, the analysts highlight six stocks - Ionis, Beam, Taysha, Sarepta, Spyre, and RAPT, as their strongest ideas for 2026, reflecting robust pipelines, near-term data ...

Brokers see modest upside for CSL, but are very bullish on this smaller rival. The post Forget CSL shares, this ASX biotech stock could triple in value appeared first on The Motley Fool Australia.